Jump to Content Jump to Main Navigation

Volume 15 (2017): Issue 8 (Aug 2017)

in Journal of the National Comprehensive Cancer Network

Online ISSN:: 1540-1413

Print ISSN:: 1540-1405

Cover Journal of the National Comprehensive Cancer Network

NCCN News

Pages: xxvii–xxix

Oncology Research Program

Pages: xxxv–xxxvi

When It's Really Good, We Know It!

By: Margaret Tempero

Pages: 973

To the Editor: How Do We Solve This Confusion?

Pages: 975–976

Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas

By: Anastasia Drobysheva, Laura J. Klesse, Daniel C. Bowers, Veena Rajaram, Dinesh Rakheja, Charles F. Timmons, Jason Wang, Korgun Koral, Lynn Gargan, Erica Ramos and Jason Y. Park

Pages: 978–982

Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer

By: Ahmad Hamad, Aatur D. Singhi, Nathan Bahary, Kevin McGrath, Rula Amarin, Herbert J. Zeh and Amer H. Zureikat

Pages: 983–988

NCCN Guidelines Insights: Palliative Care, Version 2.2017

Pages: 989–997

Race- and Sex-Based Disparities in the Therapy and Outcomes of Squamous Cell Carcinoma of the Anus

By: Nivedita Arora, Arjun Gupta, Hong Zhu, Alana Christie, Jeffrey J. Meyer, Saad A. Khan and Muhammad S. Beg

Pages: 998–1004

The Evolution of Metastatic Colorectal Cancer Clinical Trials: Application of the ASCO Framework for Assessing Value

By: Doreen A. Ezeife, Sunil Parimi, Ellen R. Cusano, Matthew K. Smith, Tony H. Truong, Soundouss Raissouni, Yongtao Lin, Jose G. Monzon, Haocheng Li, Vincent C. Tam and Patricia A. Tang

Pages: 1005–1013

Costs and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancer

By: Janice S. Kwon, Gary Pansegrau, Melica Nourmoussavi, Geoffrey L. Hammond and Mark S. Carey

Pages: 1015–1021

Short- and Long-Term Survival in Metastatic Pancreatic Adenocarcinoma, 1993–2013

By: Talia Golan, Tal Sella, Ofer Margalit, Uri Amit, Naama Halpern, Dan Aderka, Einat Shacham-Shmueli, Damien Urban and Yaacov Richard Lawrence

Pages: 1022–1027

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Pages: 1028–1061

DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development

By: Talia Golan and Milind Javle

Pages: 1063–1069

Trends in Neoadjuvant Approaches in Pancreatic Cancer

By: Lingling Du and Andrea Wang-Gillam

Pages: 1070–1077

Acting on Rare Driver Alterations: Is Getting a Meaningful Response a Game of Chance or Scientific Rigor?

By: David R. Braxton

Pages: 1078–1080